stockrowIQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024.
- Revenue
- +8.00%
- EPS
- +10.2%
- Free cash flow
- −21.3%
- Total debt
- +7.42%
Quarter to September 2026, against a year earlier
Follow IQV
Alert me
IQVIA Holdings Inc. (IQV) EPS (diluted)
IQVIA Holdings Inc.'s EPS (diluted) for fiscal 2025 was $7.84, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $8.24. Over the past ten years it has ranged from $0.47 (fiscal 2016) to $7.84 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 6 consecutive fiscal years. IQVIA Holdings Inc. ranks 7th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $7.84 | 4.67% |
| FY2024 | $7.49 | 2.74% |
| FY2023 | $7.29 | 27.45% |
| FY2022 | $5.72 | 15.56% |
| FY2021 | $4.95 | 246.15% |
| FY2020 | $1.43 | 48.96% |
| FY2019 | $0.96 | (22.58%) |
| FY2018 | $1.24 | (78.91%) |
| FY2017 | $5.88 | 1,151.06% |
| FY2016 | $0.47 | (84.74%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.11 | 37.76% |
| Jun 2026 | $1.53 | (4.97%) |
| Mar 2026 | $1.61 | (46.15%) |
| Dec 2025 | $2.99 | 54.92% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. compare | $14.83 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| IQV IQVIA Holdings Inc. | $8.24 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. compare | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IQV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement